Table 2

Performance characteristics of the 2022 ACR/EULAR classification criteria for Takayasu arteritis*

Patient subsetTotal no patients (no TAK patients)Sensitivity (95% CI)Specificity (95% CI)AUC (95% CI)
Development data set639 (316)89.9 (86.0 to 93.0)96.6 (94.0 to 98.3)0.93 (0.91 to 0.95)
Validation data set273 (146)93.8 (88.6 to 97.1)99.2 (96.7 to 100.0)0.97 (0.94 to 0.99)
Age intervals
 18–39 years437 (351)94.0 (91.0 to 96.3)97.7 (91.9 to 99.7)0.96 (0.94 to 0.98)
 40–60 years226 (104)83.7 (75.1 to 90.2)91.8 (85.4 to 96.0)0.88 (0.83 to 0.92)
World regions
 North America127 (28)85.7 (67.3 to 96.0)92.9 (86.0 to 97.1)0.89 (0.82 to 0.96)
 Europe422 (130)91.5 (85.4 to 95.7)94.9 (91.7 to 97.1)0.93 (0.90 to 0.96)
 North America/Europe combined549 (158)90.5 (84.8 to 94.6)94.4 (91.6 to 96.4)0.92 (0.90 to 0.95)
 Asia357 (298)92.0 (88.3 to 94.8)93.2 (83.5 to 98.1)0.94 (0.89 to 0.96)
  • *Performance characteristics for the age and regional subsets were reported using data from the combined development and validation data sets to maximise sample size.

  • ACR, American College of Rheumatology; AUC, area under the curve; TAK, Takayasu arteritis.